Comparative Pharmacology
Head-to-head clinical analysis: EXSEL versus SANSAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXSEL versus SANSAC.
EXSEL vs SANSAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
SANSAC is a synthetic peptide that acts as a selective antagonist of the vasopressin V2 receptor, thereby inhibiting water reabsorption in the renal collecting ducts and promoting aquaresis.
1-2 mg orally once daily; maximum dose 2 mg/day.
For adult patients, the recommended dose of SANSAC is 500 mg administered orally twice daily with or without food.
None Documented
None Documented
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min).
The terminal elimination half-life is approximately 12-15 hours in healthy adults, with clinical significance for once-daily dosing. In patients with renal impairment (CrCl <30 mL/min), the half-life may be prolonged up to 24-36 hours, requiring dose adjustment.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Renal excretion accounts for approximately 60-70% of the administered dose as unchanged drug, with an additional 10-15% as metabolites. Fecal elimination constitutes 10-15% mainly via biliary secretion. Less than 5% is eliminated via other routes.
Category C
Category C
Topical Antifungal
Topical Antifungal